The Money Man Behind Rick Santorum: Who Is Foster S. Friess?
Savings Experiment: Snow Removal
Gilead Sciences (GILD - option chain) stock is trading lower today after the company announced last night that its hypertension treatment darusentan missed the primary goal of a Phase III trial. As a result, GILD says it has ended development of the drug in favor of spending resources on other products in its pipeline. If you think this stock won't be rising too far in the coming months, then it could be a good time to look at a bearish hedged play on GILD.This morning, GILD opened at $45.90. So far today the stock has hit a high of $46.28 and a low of $45.01. As of 12:15, GILD is trading at $45.18, down $1.78 (-3.8%). The chart for GILD looks bullish and S&P gives GILD a positive 5 STARS (out of 5) strong buy ranking.
For a bearish hedged play on this stock, I would consider a February bear-call credit spread above the $50 range. A bear-call credit spread is an options position that combines the purchase and sale of call options to hedge risk in case the stock doesn't do what you think but still leverage nice returns. For this particular trade, we will make an 11.1% return in two months as long as GILD is below $50 at February expiration. Gilead would have to rise by more than 10% before we would start to lose money. Learn more about this type of trade here.
GILD hasn't been above $50 at all since February and has shown resistance around $47.50 recently.
Brent Archer is an options analyst and writer at Investors Observer.
DISCLOSURE: Mr. Archer owns and/or controls diversified portfolios of long and short stock and option positions that may include holdings in companies he writes about. At publication time, Brent neither owns nor controls positions in GILD.
Goldman Earnings Sink After Buffett Dividend
Johnson & Johnson's Income Falls 23%
Burberry Shares Leap on Sales Update
